Abstract:
To study the hepatoprotective and clinical effectiveness of the drug Heptral in the complex treatment
of patients with rheumatoid arthritis. Materials and methods: The study, using clinical laboratory, biochemical tests
and ultrasound, studied the functional state of the liver in 64 patients with rheumatoid arthritis who were treated at
the TMA multidisciplinary clinic. The patients were divided into 2 groups. 31 patients of the main group in addition to
standard therapy received the drug ademetionine (Heptral) at a dose of 500 mg infusion solution for 1 day, once a day.
Standard treatment was carried out in group 2 (33 patients). Results: 65% of patients in group 1 and 12% of patients
in group 2 showed normalization of ALT. Normalization of AST indicators was observed in 59% of patients in group 1
and in 14% in group 2. Alkaline phosphatase decreased by 30% in group 1, and total bilirubin in this group decreased
by 55%. Hepatomegaly was observed in 9 patients before treatment; after 4 weeks of taking ademetionine, liver sizes
returned to normal in 2 patients (22.2%), and in 7 patients (77.8%) who took ademetionine for 3 months, liver sizes returned
to normal. Conclusion: The use of the drug Ademethionine in combination with the main treatment can reduce
the severity of hepatotoxic reactions and prevent situations requiring temporary withdrawal of the main treatment.
